Journey Medical Corporation
DERM | NASDAQ
$7.25
+$0.26 (+3.72%)
At close: Sep 22, 2026, 4:00 PM ET
$7.25
$0 (0.00%)
After-hours:
Sep 22, 2026, 7:30 PM ET
Company Profile
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Key Executives
| Name | Position |
|---|---|
| Claude Maraoui | Founder, President, Chief Executive Officer & Director |
| Joseph Benesch | Chief Financial Officer & Corporate Controller |
| Ramsey Alloush | Chief Operating Officer, General Counsel & Company Secretary |
| Brian Prout | Executive Director of Marketing |
| Jaclyn Jaffe | Senior Director of Corporate Operations |
| Lindsay Allan Rosenwald | Executive Chairman |
| Louis Donati | Director of Market Access |
| Robert Nevin | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 12, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 15, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jun 29, 2026 | 4 | Filing |
| Jun 26, 2026 | 4 | Filing |
| Jun 26, 2026 | 4 | Filing |
Journey Medical Corporation
| Country | United States |
| IPO Date | Nov 11, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Claude Maraoui |
Contact Details
9237 East Via de Ventura Boulevard Scottsdale,
Arizona 85258 United States
Stock Details
| Ticker Symbol | DERM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001867066 |
| CUSIP Number | 48115J109 |
| ISIN Number | US48115J1097 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove DERM